CLINICAL EVIDENCE

REGENPRP™-HA COMBINATION FOR KNEE OA: RIGLET 2026

The RegenPRP™-HA combination prepared with Cellular Matrix demonstrated significant clinical benefit and a favorable safety profile in patients with moderate knee osteoarthritis compared with a single injection of crosslinked hyaluronic acid (Synvisc-One®).

50.6% of patients achieved an acceptable symptom state for pain at 6 months

compared with 33.3% following treatment with crosslinked hyaluronic acid alone.

Clinical Evidence

A prospective, multicenter, randomized controlled trial evaluated the efficacy and safety of a single injection of RegenPRP™-HA prepared with Cellular Matrix versus a single injection of Synvisc-One® in patients with symptomatic moderate knee osteoarthritis. Follow-up assessments were performed at 1, 3 and 6 months.

  • Number of patients: 156 (81 PRP-HA; 75 HA)
  • Mean age: 59.6 years
  • Kellgren-Lawrence grade II and III knee osteoarthritis
  • Single intra-articular injection under ultrasound guidance

RESULTS

  • Significant improvement in pain and function was observed in both treatment groups during follow-up.
  • PRP-HA demonstrated a significantly greater improvement in WOMAC pain on walking at 6 months compared with crosslinked HA alone (p=0.04).
  • More patients achieved an acceptable symptom state for pain (PASS criterion) at 6 months with PRP-HA than with crosslinked HA alone (50.6% vs 33.3%, p=0.03).
  • The incidence of adverse events was low and comparable between groups (7.4% vs 5.3%). Most events consisted of transient post-injection pain or swelling.

PASS Responders at 6 Months (%)

% Responders

  • RegenPRP™-HA 50.6%
  • Synvisc-One® 33.3%

CONCLUSION

This randomized controlled trial demonstrated that a single injection of RegenPRP™-HA prepared with Cellular Matrix is a safe and effective treatment option for patients with moderate knee osteoarthritis, providing significant improvement in pain and a higher proportion of patients achieving an acceptable symptom state at 6 months compared with crosslinked hyaluronic acid alone.

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

RegenWound

RegenWound is a fully autologous solution prepared from the patient’s own blood, with the objective of providing a standardised and reproducible approach for clinical use.

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EU-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.